https://doi.org/10.55788/a6f0ff58
Nearly 12% of patients with inflammatory bowel disease (IBD) develop deterioration of kidney function within 10 years of IBD diagnosis. However, an ICD-code for chronic kidney disease was only present in 6.4% at this timepoint.
A Swedish, observational, cohort study used the healthcare utility database SCREAM to evaluate kidney-related complications in patients with IBD, a topic with insufficient scientific results to date [1]. Around 1.7 million people without IBD who had baseline values of an estimated glomerular filtration rate (eGFR) on file as of 2006 were followed until death, emigration, or the end of 2019. The primary composite outcome was any kind of chronic kidney disease (CKD) events and consisted of a ≥30% decrease in eGFR or kidney failure subsumed as CKD progression. To calculate absolute risks, cases of incident IBD within the follow-up period were matched with up to 5 controls from the reference population.
“After a median follow-up of 9 years we observed about 10,000 IBD cases, which is about 0.6% of the entire cohort,” Dr Yuanhang Yang (Karolinska Institutet, Sweden) stated. Within 10 years after an IBD diagnosis, 11.8% of the patients developed CKD. This corresponded to a 25% increased relative risk of the primary outcome. Of note, only 6.4% had received a diagnosis (ICD code 10) for CKD at the 10-year follow-up. The adjusted hazard ratio (HR) of CKD progression was 1.11 (P=0.041). In addition, the relative risks for acute kidney injury, kidney stones, and secondary amyloidosis were significantly elevated with an HR of 1.97, 1.69, and 2.77, respectively.
When differentiating according to an IBD diagnosis of either Crohn’s disease (CD) or ulcerative colitis (UC), the relative risk of having any kind of CKD event was higher for those with CD: HR 1.40 for CD versus 1.10 for UC. “We also did a subgroup analysis between men and women and we found no major difference,” Dr Yang added.
Dr Yang underlined that a higher risk of acute kidney injury has not been previously recognised in the literature. “Our findings bring to attention that we need to establish protocols for kidney function monitoring, and, of course, referral to nephrological care for IBD patients,” Dr Yang concluded.
- Yang Y. Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease. OP07, ECCO 2023, 01–04 March, Copenhagen, Denmark.
Posted on
« Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD Next Article
OCT non-inferior to biopsy in basal cell carcinoma »
Table of Contents: ECCO 2023
Featured articles
What Is New in Biologic Therapy?
Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD
Long-term data supports the established efficacy and safety of ustekinumab in UC
Anti-TNF withdrawal may be a safe option in stable IBD
Intensified drug therapy leads to better stricture morphology in CD
Small Molecules in IBD: State of the Art
Continued efficacy of long-term ozanimod as UC treatment
Upadacitinib successful in the management of both CD and UC
Solid results for long-term therapy of UC with filgotinib
Paediatric IBD: What You Need To Know
Perinatal period is crucial for the risk of developing CD
Early-life antibiotic exposure: a risk factor for paediatric-onset IBD
Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk
Risk Factors and Complications of IBD
Checking kidney function is important during the course of IBD
Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD
Surgical Approaches: New Developments
Long-term resection potentially better than anti-TNF treatment in CD
Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure
Pearls of the Posters
Drop in overall IBD procedures during the pandemic
Proton pump inhibitors associated with worse outcomes in CD
Poor sleep in CD linked to low levels of vitamin D
Novel AI tool assessing mucosal inflammation achieves high correlation with histopathologists
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy